Neogenomics (NEO) Aktie Kurs
Neogenomics Kurs
De seneste 19 år voksede Neogenomicss omsætning med 28,2 % årligt og nåede 727,33 Mio. USD. Indtjening pr. aktie er vokset med 50,4 % om året de seneste 8 år. For Neogenomics er nettoavance på -14,9 % ned i forhold til -1,7 % for et par år siden. Konsensus 12-måneders kursmål for Neogenomics er 19,00 USD, cirka over kursen med 14,4 %. Af 16 analytikere anbefaler 11 køb — den samlede vurdering er Køb.
Neogenomics aktiekurs
Hent disse data via Eulerpool API
100.000 requests/md. gratis · intet kreditkort
Neogenomics aktie og aktieanalyse
Hyppigt stillede spørgsmål om Neogenomics-aktien
Neogenomics Inc. (NYSE: NEO) is a leading provider of cancer-focused genetic testing services. The company's business model revolves around offering comprehensive testing solutions that aid in the diagnosis and treatment of cancer patients. Neogenomics Inc. operates through a network of laboratories and provides advanced molecular and cytogenetic testing, helping healthcare professionals make informed decisions based on genetic information. With a focus on precision medicine, Neogenomics Inc. delivers personalized treatment options, improving patient outcomes and delivering high-quality diagnostic services.
Neogenomics Inc is primarily active in the healthcare and diagnostic laboratory services industries.
The main competitors of Neogenomics Inc in the market are Laboratory Corporation of America Holdings (LabCorp), Quest Diagnostics Incorporated, and NeoGenomics Laboratories.
Neogenomics Inc is a leading provider of cancer-focused genetic testing services. Founded in 2001, the company is headquartered in Fort Myers, Florida. With an extensive network of laboratories across the United States, Neogenomics offers cutting-edge diagnostic and pharmaceutical services to aid in the personalized treatment and monitoring of various types of cancers. Over the years, Neogenomics has grown its portfolio of tests and services, catering to the evolving needs of healthcare professionals and patients. Their dedication to innovation and quality has positioned them as a trusted partner in the fight against cancer.
Some significant milestones achieved by Neogenomics Inc include its acquisition of Clarient Inc in 2015, which expanded its personalized medicine capabilities. The company also received full approval from the New York State Department of Health in 2017, allowing it to offer its services in all 50 states. Neogenomics Inc has strengthened its position in the molecular testing market through strategic collaborations with pharmaceutical companies. Furthermore, in 2019, the company completed its acquisition of Genoptix, enhancing its oncology diagnostics capabilities. These milestones demonstrate Neogenomics Inc's commitment to growth and innovation in the field of cancer diagnostics and personalized medicine.
Neogenomics Inc is primarily present in the United States.
Neogenomics Inc prides itself on its commitment to excellence and innovation in the field of precision medicine. With a strong corporate philosophy centered around patient care and advancing the fight against cancer, Neogenomics Inc places great importance on ethical practices and providing accurate diagnostic solutions. The company believes in fostering a collaborative environment to bring cutting-edge technologies and personalized medicine to patients globally. By constantly pushing boundaries and embracing transformative ideas, Neogenomics Inc aims to revolutionize how cancer is detected and treated. Through its dedication to quality, integrity, and patient-centric values, the company sets itself apart as a leader in the field.
Analytikere sætter i øjeblikket et gennemsnitligt kursmål på 19,00 USD for Neogenomics-aktien (median: 19,00 USD), svarende til +14,4 % i forhold til seneste kurs. Konsensus bygger på 16 analytikervurderinger.
16 analytikere vurderer i øjeblikket Neogenomics-aktien: 11 anbefaler køb, 5 hold og 0 salg. For 2026 forventer analytikere, at Neogenomics genererer omsætning på 805,18 Mio. USD og indtjening pr. aktie på 0,92 USD.
Omregnet til den aktuelle valutakurs handles Neogenomics-aktien til 14,80 EUR (16,61 USD).
Neogenomics-aktien (NEO) er noteret på 5 børser, herunder: NASDAQ (NEO), SIX (Zürich) (NG9.SW), Frankfurt (NG9.F), München (NG9.MU), Düsseldorf (NG9.DU).
Neogenomics Inc is a leading company in oncology diagnostics and offers a wide range of solutions and products to its customers. The company has been listed on the stock exchange since 2001 and is the largest provider of cancer diagnostics services in the United States. Translate the text to the best possible English.
forventet-omsætningen for Neogenomics er 805,18 Mio. USD. Dette tal er baseret på aktuelle finansielle data og afspejler virksomhedens forretningsydeevne.
forventet-overskuddet for Neogenomics er 23,72 Mio. USD. Nettooverskuddet afspejler virksomhedens rentabilitet efter fradrag af alle udgifter.
Pris-til-indtjening-forholdet (P/E) for Neogenomics er i øjeblikket 18,02. P/E-forholdet sammenligner den nuværende aktiekurs med indtjeningen pr. aktie og hjælper investorer med at vurdere værdiansættelsen af Neogenomics-aktien.
Pris-til-salgs-forholdet (P/S) for Neogenomics er i øjeblikket 0,53. P/S-forholdet sammenligner markedskapitalisering med årlig omsætning og fungerer som en værdiansættelsesmetrik for Neogenomics-aktien.
AlleAktien-kvalitetsscore for Neogenomics er 3/10.
ISIN for Neogenomics er US64049M2098. ISIN (International Securities Identification Number) er en globalt unik identifikator for værdipapirer.
WKN for Neogenomics er 120159. WKN (Wertpapierkennnummer) er et seks-cifret tysk identifikationsnummer for værdipapirer.
Tickeren for Neogenomics er NEO. Tickersymbolet bruges til at handle Neogenomics-aktier på børsen.
Neogenomics aktie
Neogenomics Peer Group
Neogenomics Ticker
Neogenomics FIGI
Alle fundamentale data om Neogenomics i deep dive
Vores aktieanalyse af Neogenomics-aktien indeholder vigtige finansielle nøgletal som omsætning, profit, P/E-ratioen, P/S-ratioen, EBIT samt informationer om udbytte. Desuden ser vi på aspekter som aktier, markedskapitalisering, gæld, egenkapital og forpligtelser hos Neogenomics. Hvis du søger mere detaljerede oplysninger om disse emner, tilbyder vi på vores undersider omfattende analyser: